Please login to the form below
Erivedge
This page shows the latest Erivedge news and features for those working in and with pharma, biotech and healthcare.
Pfizer gets first FDA nod for hedgehog inhibitor in AML
The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and
Latest news
-
NICE backs Pfizer’s Xeljanz for RA
Roche’s Erivedge (vismodegib) - which was made available via the old CDF in 2013 - is also set to be cut from the scheme, but patients who are currently receiving the drug
-
Pfizer's SMO inhibitor boosts survival in blood cancer trial
There are already two SMO (smoothened) inhibitors on the market - Novartis' Odomzo (sonidegib) and Roche's Erivedge (vismodegib) - and both are approved to treat a form of skin cancer known as ... Sales of Erivedge were around $150m in the first nine
-
EU green light for Novartis' skin cancer therapy
It will compete in the marketplace against Roche's Erivedge (vismodegib), another SMO inhibitor that has been on the market since 2012 and achieved sales of 72m Swiss francs ($75m) in ... Neither drug is expected to be a big seller thanks to the small
-
FDA approves four new medicines across multiple areas
The pill will compete against Roche's Erivedge (vismodegib), which was the first oral drug for BCC to see approval in 2012, although neither medicine is expected to be a blockbuster
-
Novartis skin cancer drug clears pivotal trial
This pathway is also targeted by Roche's Erivedge (vismodegib), which was granted approval as a BCC therapy in the US in 2012 and in Europe last year. ... Erivedge sales rocketed more than 160 per cent to reach 75m Swiss francs ($84m) last year has been
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Chris Bowden joins Agios
During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
-
Curis looks to MedImmune and Takeda for new hires
Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
-
Principal Medical Writer
-
Varies on experience
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Content Editor - Biotechnology
-
Salary TBC
-
Account Management
-
Competitive Salary Offered
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Bedrock Group rebrands as Resonant Group
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Moderna launches COVID-19 vaccine booster study to address new variants
- WHITE PAPER: Why do men die younger?
- Opdivo improves survival in oesophageal cancer
- Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
- UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- WHITE PAPER: Why do men die younger?
- It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
- 3 tips to show patient diversity in your clinical trial materials
- Here are some useful tips to help get your hands on authentically diverse stock photos....
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
Quick links
Infographics
